Immunomodulation for stroke-associated pneumonia: a systematic review of mechanistic insight and emerging therapeutic strategies in animal models - Scorecard - MDSpire

Immunomodulation for stroke-associated pneumonia: a systematic review of mechanistic insight and emerging therapeutic strategies in animal models

  • By

  • Xiangyun Chen

  • Yihe Xu

  • Yonghong Gao

  • Xinxing Lai

  • Rufan Xu

  • Hongrui Zhang

  • Na Li

  • Zhenhong Liu

  • Ying Gao

  • July 16, 2026

Share

Clinical Scorecard: Immunomodulatory Approaches for Pneumonia Related to Stroke: A Comprehensive Review of Mechanisms and Novel Treatment Strategies in Animal Research

At a Glance

CategoryDetail
ConditionStroke-associated pneumonia (SAP)
Key MechanismsStroke-induced immunosuppression, sympathetic nervous system overactivation, disruption of the gut-lung axis, and active intercellular suppression.
Target PopulationPatients with stroke at risk of pneumonia.
Care SettingClinical research and experimental models.

Key Highlights

  • 30% of acute stroke patients develop infections, with pneumonia rates as high as 10%.
  • Systemic immunosuppression is linked to increased susceptibility to bacterial infections.
  • Immunomodulatory therapies show promise in preclinical models for preventing or treating SAP.
  • Current treatment strategies for SAP are limited and face challenges from drug-resistant bacteria.
  • Emerging mechanisms include the role of the cholinergic anti-inflammatory pathway and gut microbiota dysbiosis.

Guideline-Based Recommendations

Diagnosis

  • Evaluate immune mechanisms underlying pneumonia in stroke patients.

Management

  • Consider immunomodulatory therapies targeting immune dysregulation in SAP.

Monitoring & Follow-up

  • Monitor for signs of pneumonia in stroke patients due to high infection risk.

Risks

  • Increased mortality associated with pneumonia in stroke patients.

Patient & Prescribing Data

Patients with stroke experiencing pneumonia.

Immunomodulatory approaches are experimental and require further validation for clinical use.

Clinical Best Practices

  • Adopt a systematic approach to understanding immune dysregulation in stroke.
  • Integrate findings from preclinical studies into clinical practice cautiously.

Related Resources & Content

    Original Source(s)

    Related Content